Evidence map›Paper›PMID 35995991›Full record

ArticleJournal of neurology2022

Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.

Marlène Barnay, Fanny Duval, Guilhem Solé, Louis Carla, Stéphane Mathis, Gwendal Le Masson

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Immunoglobulin for myasthenia gravis.The Cochrane database of systematic reviews · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marlène BarnayNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Fanny DuvalNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Guilhem SoléNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Louis CarlaNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Stéphane MathisNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France. stephane.mathis@chu-bordeaux.fr.ORCID http://orcid.org/0000-0003-0775-4625
Gwendal Le MassonNerve-Muscle Unit, ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Université de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo describe the efficacy of subcutaneous immunoglobulin (SCIg) in patients with myasthenia gravis (MG).

methodsThis was a retrospective study conducted in the neuromuscular referral center of Bordeaux (between January 1, 2014 and March 31, 2021) with MG patients treated with SCIg. The main outcome was SCIg efficacy assessed by the before and after SCIg Myasthenia Gravis Foundation of America (MGFA) clinical classification, the duration of hospitalization and the number of days of orotracheal intubation (OTI).

resultsSixteen patients were included in the study (11 females; 5 males). Nine patients were still treated with SCIg at the end of the study (March 31, 2021) and then underwent prospective follow-up. The average age of the patients was 56.1 (19-83) years. The median duration of MG at onset of SCIg was 37.4 months. Eight patients (50%) remained stable (4 in stage MGFA-IV and 4 in MGFA-III). Eight patients (50%) improved: 3 from MGFA-IV to MGFA-III, 1 from MGFA-IV to MGFA-II, 1 from MGFA-IV to MGFA-I, 2 from MGFA-III to MGFA-II and 1 from MGFA-III to MGFA-I (no patient worsened). The duration of disease progression did not appear to affect the response to SCIg therapy. The number of hospital days per month was significantly reduced after SCIg compared to before, and the number of days in intensive care unit and the number of days of OTI were also reduced. Only minor adverse effects were noted, and 80% of patients were in favor of continuing SCIg.

conclusionsSCIg is a well-tolerated and useful treatment in MG, offering interesting perspectives in the management of MG patients. However, further large-scale prospective studies are needed to confirm these results.

Indexed as

Myasthenia GravisAgedAged, 80 and overFemaleHumansImmunization, PassiveImmunoglobulinsMaleMiddle AgedProspective StudiesRetrospective StudiesImmunoglobulinsManagementMyasthenia gravisSCIgSubcutaneous immunoglobulinTreatment

Identifiers

PMID35995991
PMCPMC9395862
OpenAlexW4292707680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.